Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation

scientific article published on 25 June 2007

Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/SJ.BMT.1705751
P698PubMed publication ID17589530

P50authorCarlos A RamosQ38329408
Emel GurkanQ57840558
Richard E ChamplinQ89187648
Rima M SalibaQ114428014
P2093author name stringde Lima M
Lichtiger B
Anderson BS
Patah PA
P2860cites workClinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trialQ33329515
Platelet alloantibodies in transfused patientsQ33337692
Single donor versus pooled random donor platelet concentratesQ33339326
The definition of refractoriness to platelet transfusionsQ33350432
Optimizing platelet transfusion therapyQ33361167
Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patientsQ33364823
Influence of antibiotics on posttransfusion platelet increment.Q33497804
Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusionsQ33501221
Intravascular and total body platelet equilibrium in healthy volunteers and in thrombocytopenic patients transfused with single donor plateletsQ33503019
Pooled platelet concentrates: maybe not fancy, but fiscally sound and effectiveQ33581221
Single donor platelets: can we afford to use them? Can we afford not to use them?Q33581227
Diagnosis and management of refractoriness to platelet transfusionQ34494961
Selecting donors of platelets for refractory patients on the basis of HLA antibody specificityQ48623928
Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trialQ73594688
Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractorinessQ73905982
Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantationQ74249650
Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation--a prospective analysisQ77302850
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectstem cell transplantationQ65592366
P304page(s)461-464
P577publication date2007-06-25
P1433published inBone Marrow TransplantationQ4941523
P1476titleEfficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation
P478volume40

Reverse relations

cites work (P2860)
Q37867952A general change of the platelet transfusion policy from apheresis platelet concentrates to pooled platelet concentrates is associated with a sharp increase in donor exposure and infection rates
Q24186913A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
Q44720880Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components
Q37508075Blood Product Supply in Germany: The Impact of Apheresis and Pooled Platelet Concentrates.
Q37715077Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality
Q24187751Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
Q24186359Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
Q34791060Efficacy and Adverse Events of Platelet Transfusion Product-Specific Differences
Q45995264Immunohematopoietic stem cell transplantation in Cape Town: a ten-year outcome analysis in adults.
Q33417080Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation
Q24197779Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation
Q83305360[Use of platelet concentrates: a regional experience]

Search more.